Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,265 across all filing types
Latest filing 2021-04-28 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Price movement
Regulatory Filings Classification · 95% confidence The document is a letter from AstraZeneca Pharma India Limited to the National Stock Exchange of India regarding a query about unusual price movement. It states that the company has no information or pending announcements that could affect the stock price or volume. The document is short (1102 characters) and is a regulatory communication responding to a surveillance query. It does not contain financial data, report content, or detailed disclosures. It is a regulatory filing responding to a compliance inquiry under SEBI listing obligations. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance communication.
2021-04-28 English
We refer to our earlier communication dated December 20, 2020 intimating the receipt of Import and Market Permission in Form CT-20 (Marketing Authorization- Additional Indication) from ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) announcing the launch of a pharmaceutical product, Benralizumab (Fasenra™), in India. It references a prior communication about marketing authorization but primarily serves as an update on the product launch. There are no financial statements, earnings data, or regulatory filings related to financial performance. The document is short (1406 characters) and is an announcement rather than a report or detailed filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings related to financial disclosures. The best fitting category is a general Regulatory Filing (RNS) as it is a regulatory announcement to stock exchanges about a business update.
2021-04-20 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) announcing the launch of a pharmaceutical product, Benralizumab (Fasenra™), in India. It references a prior communication about marketing authorization but primarily serves as an update on the product launch. There are no financial statements, earnings data, or regulatory filings related to financial performance. The document is short (1406 characters) and is an announcement rather than a report or detailed filing. It does not fit categories like Annual Report, Earnings Release, or Regulatory Filings related to financial disclosures. The best fitting category is a general Regulatory Filing (RNS) as it is a regulatory announcement to stock exchanges about a business update.
2021-04-20 English
As required under Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we furnish herewith a Certificate issued by the Practicing Company Secretary ....
Regulatory Filings
2021-04-16 English
As required under Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we furnish herewith a Certificate issued by the Practicing Company Secretary ....
Regulatory Filings
2021-04-16 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2021-04-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.